Cannabis News
Home » Archives for December 2023

Month: December 2023

WednesdayDec 27, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Provides Superior Drug and API Delivery with Patented DehydraTECH Technology

Lexaria, a global innovator in drug delivery platforms, has made incredible strides in 2023, most recently seeing interim results from its human pilot study evaluating its DehydraTECH(TM) technology for the oral delivery of GLP-1 drug, semaglutide The company has also grown its patent portfolio to 37, with many others pending worldwide For 2024, the company expects to maintain the same momentum, building on the success and achievements, and plans to double down on licensing its technology Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, in this past year, has demonstrated growing success in providing healthier delivery methods…

Continue Reading

ThursdayDec 21, 2023 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) To File its IND Application with the FDA for its planned U.S. Phase 1b Hypertension Clinical Trial

Lexaria, a global innovator in drug delivery platforms, expects to submit its IND application for its planned U.S. Phase 1b Hypertension Clinical Trial with the FDA within the next 45 days The HYPER-H23-1 clinical study will build on five successful human clinical trials conducted so far, studying the company’s patented DehydraTECH(TM)-processed CBD in an aggregate total of 134 individuals Lexaria’s patented DehydraTECH(TM) “drug delivery platform technology” increases bioavailability, improving the way active pharmaceutical ingredients (“APIs”) enter the bloodstream Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced that it anticipates submitting its Investigational New Drug (“IND”)…

Continue Reading

WednesdayDec 13, 2023 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyes Additional Revenue Opportunities for 2024; Continues to Generate New Data for its DehydraTECH Technology

Lexaria, a global innovator in drug delivery platforms, is projected by Zacks SCR to be valued at $10 a share, up from the current $1.50 for 2024 Zacks SCR projects a 259% YOY revenue growth for 2024 and a 20% growth for 2025, dependent upon the ultimate approval and commercialization of products employing its patented DehydraTECH(TM) technology Lexaria also anticipates FDA approval for its IND application and commence its Phase 1b hypertension clinical trial, all in 2024 Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has had significant developments in 2023. Most notably, the company has seen…

Continue Reading

TuesdayDec 05, 2023 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Positive Interim Results in Ongoing GLP-1 Human Pilot Study

Lexaria, a global innovator in drug delivery platforms, just announced additional positive interim results from its ongoing GLP-1 human pilot study The study seeks to provide an early-stage indication of whether DehydraTECH(TM) processing could improve oral drug delivery characteristics of the GLP-1 drug semaglutide Lexaria’s DehydraTECH GLP-1 showed a 2.9% to 14.6% blood glucose level reduction relative to baseline, compared to 1.3% to 6.7% for the control group The DehydraTECH GLP-1 group also only saw a 5.3% spike in glucose levels after having a standardized meal at the 240-minute mark and a snack at the 360-minute mark, compared to 22.7%…

Continue Reading

FridayDec 01, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Building a Global Presence with Superior Delivery Technology for Wide Range of Drugs and Active Pharmaceutical Ingredients

Lexaria, a global innovator in drug delivery platforms, has, through its patented DehydraTECH(TM) technology, proven to enhance the performance of several categories of fat-soluble active molecules and drugs Since 2018, human clinical studies on the technology have yielded positive results, ultimately earning Lexaria 37 granted patents globally, with many more pending around the world With the strides made so far, Lexaria looks to grow its revenue and commercial opportunities through licensing Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, remains committed to its mission to provide healthier delivery methods of drugs and other Active Pharmaceutical Ingredients (“APIs”).…

Continue Reading

CanadianCannabisWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 905.674.5977

40 King Street West
Suite 1700-CNW
Toronto, ON M5H 3Y2
(905) 674-5977

Copyright © . CanadianCannabisWire / 40 King Street West, Suite 1700-CNW, Toronto, ON M5H 3Y2 (905) 674-5977 / Disclaimers